Alchemab unveils Alzheimer’s candidate ATLX-1088 targeting CD33 at the Antibody Industrial Symposium 2023
Alchemab’s Sandrine Legg, Director of Phenotypic Screening presented data on a potential first-in-class disease-modifying therapeutic for Alzheimer’s disease at the Antibody Industrial Symposium in Tours, France on 22 June 2023.